Clinical Trial Update: Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera [Phase 3]

View source ↗

Summary

A phase 3 long-term safety study of Rusfertide (PTG-300) in polycythemia vera is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• Rusfertide (PTG-300)

Snippet

Sponsor: Protagonist Therapeutics, Inc. | Conditions: Polycythemia Vera | Phase 3 | Status: ACTIVE_NOT_RECRUITING